THEM6 and posterior cortical atrophy: To further demonstrate the importance of THEM6 in clinical PCa, we performed IHC on a tissue microarray (TMA, n = 297, Table EV5) comprised of tumours obtained from treatment‐naïve (Untreated), treatment‐responsive (neoadjuvant hormonal therapy, NHT‐treated), treatment‐resistant (CRPC) and neuroendocrine (NEPC) PCa patients (Figs 6E and EV6C).